Details of the Drug Combination

General Information of Drug Combination (ID: DCYX5MK)

Drug Combination Name
Cocaine Vigabatrin
Indication
Disease Entry Status REF
Cocaine Dependence Phase 1 [1]
Component Drugs Cocaine   DMSOX7I Vigabatrin   DMYT0OG
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Cocaine
Disease Entry ICD 11 Status REF
Anaesthesia 9A78.6 Approved [2]
Cocaine addiction 6C45.2 Approved [3]
Cocaine Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [11]
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Inhibitor [11]
Dopamine transporter (DAT) TTVBI8W SC6A3_HUMAN Inhibitor [11]
------------------------------------------------------------------------------------
Cocaine Interacts with 5 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [12]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [13]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [14]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [15]
Butyrylcholine esterase (BCHE) DEIHSMD CHLE_HUMAN Metabolism [16]
------------------------------------------------------------------------------------
Cocaine Interacts with 184 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cocaine esterase (CES2) OTC647SQ EST2_HUMAN Decreases Expression [6]
Cytoplasmic dynein 1 intermediate chain 1 (DYNC1I1) OTFX1KCG DC1I1_HUMAN Decreases Expression [6]
Septin-4 (SEPTIN4) OTD16B30 SEPT4_HUMAN Decreases Expression [6]
LIM domain-binding protein 2 (LDB2) OT6Y8IEK LDB2_HUMAN Decreases Expression [6]
Phospholipid phosphatase 2 (PLPP2) OT0BQAXX PLPP2_HUMAN Decreases Expression [6]
Neurofilament light polypeptide (NEFL) OTQESJV4 NFL_HUMAN Decreases Expression [6]
Neurofilament medium polypeptide (NEFM) OT8VCBNF NFM_HUMAN Decreases Expression [6]
Profilin-1 (PFN1) OTHTGA1H PROF1_HUMAN Increases Expression [6]
Cytochrome c1, heme protein, mitochondrial (CYC1) OT0962IM CY1_HUMAN Decreases Expression [6]
Small ribosomal subunit protein uS2 (RPSA) OTJZHEGT RSSA_HUMAN Decreases Expression [6]
Gamma-enolase (ENO2) OTRODL0T ENOG_HUMAN Decreases Expression [6]
Guanine nucleotide-binding protein G(o) subunit alpha (GNAO1) OTPB1RGK GNAO_HUMAN Decreases Expression [6]
Clathrin light chain B (CLTB) OTPW9VRE CLCB_HUMAN Decreases Expression [6]
Cytochrome c oxidase subunit 6C (COX6C) OT3V7JE5 COX6C_HUMAN Decreases Expression [6]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Decreases Expression [6]
Receptor-type tyrosine-protein phosphatase alpha (PTPRA) OTZA82J1 PTPRA_HUMAN Decreases Expression [6]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Increases Expression [6]
Malate dehydrogenase, cytoplasmic (MDH1) OTJEO4E8 MDHC_HUMAN Decreases Expression [6]
Vesicle-fusing ATPase (NSF) OTKRJ2ZT NSF_HUMAN Decreases Expression [6]
Microtubule-associated protein 1B (MAP1B) OTVXW089 MAP1B_HUMAN Decreases Expression [6]
F-actin-capping protein subunit beta (CAPZB) OTF1A4N0 CAPZB_HUMAN Decreases Expression [6]
G protein-activated inward rectifier potassium channel 2 (KCNJ6) OTDE1FT0 KCNJ6_HUMAN Decreases Expression [6]
ATP synthase F(0) complex subunit C3, mitochondrial (ATP5MC3) OTX674BU AT5G3_HUMAN Decreases Expression [6]
Translocon-associated protein subunit delta (SSR4) OTBWBGMR SSRD_HUMAN Decreases Expression [6]
Neuronal membrane glycoprotein M6-a (GPM6A) OT8G13EG GPM6A_HUMAN Decreases Expression [6]
Mitogen-activated protein kinase 10 (MAPK10) OTC46VX1 MK10_HUMAN Decreases Expression [6]
Ataxin-3 (ATXN3) OTJVVGKT ATX3_HUMAN Decreases Expression [6]
Myelin proteolipid protein (PLP1) OT8CM9CX MYPR_HUMAN Decreases Expression [6]
Serine/threonine-protein phosphatase PP1-alpha catalytic subunit (PPP1CA) OT7Y43A1 PP1A_HUMAN Decreases Expression [6]
Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform (PPP2CB) OT24GMCM PP2AB_HUMAN Decreases Expression [6]
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1) OTLL7L74 GBB1_HUMAN Decreases Expression [6]
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform (PPP2CA) OT83PT85 PP2AA_HUMAN Decreases Expression [6]
Vacuolar fusion protein CCZ1 homolog B (CCZ1B) OT1TTYK1 CCZ1B_HUMAN Decreases Expression [6]
Interferon regulatory factor 9 (IRF9) OTK4MYQJ IRF9_HUMAN Decreases Expression [6]
Transcription factor AP-4 (TFAP4) OT1KQIUX TFAP4_HUMAN Increases Expression [6]
Paired box protein Pax-8 (PAX8) OTRPD9MI PAX8_HUMAN Increases Expression [6]
Cadherin-17 (CDH17) OT9EV2XK CAD17_HUMAN Decreases Expression [6]
Neuronal membrane glycoprotein M6-b (GPM6B) OT8Q1582 GPM6B_HUMAN Decreases Expression [6]
Rho GTPase-activating protein 29 (ARHGAP29) OT8JH4TY RHG29_HUMAN Decreases Expression [6]
Glutamate decarboxylase 1 (GAD1) OT52Z39J DCE1_HUMAN Decreases Expression [6]
Transgelin-3 (TAGLN3) OTJBP3VJ TAGL3_HUMAN Decreases Expression [6]
Catenin delta-2 (CTNND2) OTYKE30Y CTND2_HUMAN Decreases Expression [6]
Type 2 lactosamine alpha-2,3-sialyltransferase (ST3GAL6) OTB17Q43 SIA10_HUMAN Increases Expression [6]
Nuclear receptor subfamily 1 group I member 3 (NR1I3) OTS3SGH7 NR1I3_HUMAN Decreases Expression [17]
Krev interaction trapped protein 1 (KRIT1) OT58AP1I KRIT1_HUMAN Increases Expression [18]
Integrin beta-1-binding protein 1 (ITGB1BP1) OTVQFNGS ITBP1_HUMAN Increases Expression [9]
5-hydroxymethyl-dUMP N-hydrolase (DNPH1) OTEZVTI1 DNPH1_HUMAN Decreases Expression [9]
Liprin-alpha-3 (PPFIA3) OTNPZ6HT LIPA3_HUMAN Increases Expression [19]
NADH dehydrogenase iron-sulfur protein 2, mitochondrial (NDUFS2) OTBT8KW9 NDUS2_HUMAN Affects Expression [20]
Pituitary homeobox 3 (PITX3) OTE2KT8P PITX3_HUMAN Decreases Expression [21]
Deformed epidermal autoregulatory factor 1 homolog (DEAF1) OTCLX3ZW DEAF1_HUMAN Decreases Expression [9]
Claudin-11 (CLDN11) OTNN6UTL CLD11_HUMAN Decreases Expression [22]
TIP41-like protein (TIPRL) OTS2FZ8O TIPRL_HUMAN Increases Expression [18]
Protocadherin-8 (PCDH8) OTDDOQM2 PCDH8_HUMAN Increases Expression [18]
NADH dehydrogenase 1 alpha subcomplex subunit 10, mitochondrial (NDUFA10) OTBURQ3A NDUAA_HUMAN Affects Expression [20]
Apoptosis-inducing factor 1, mitochondrial (AIFM1) OTKPWB7Q AIFM1_HUMAN Increases Expression [18]
Reversion-inducing cysteine-rich protein with Kazal motifs (RECK) OT9QIHEQ RECK_HUMAN Increases Expression [18]
Adenylate kinase isoenzyme 1 (AK1) OT614AR3 KAD1_HUMAN Decreases Expression [9]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Increases Expression [23]
Natriuretic peptides A (NPPA) OTMQNTNX ANF_HUMAN Increases Expression [24]
Pro-opiomelanocortin (POMC) OTV41F7T COLI_HUMAN Increases Secretion [25]
Proenkephalin-A (PENK) OT8P3HMP PENK_HUMAN Decreases Expression [26]
Proenkephalin-B (PDYN) OTEJ6430 PDYN_HUMAN Increases Expression [9]
Lutropin subunit beta (LHB) OT5GBOVJ LSHB_HUMAN Increases Secretion [27]
Alpha-crystallin B chain (CRYAB) OTY4JGYU CRYAB_HUMAN Decreases Expression [9]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Increases Expression [28]
Platelet basic protein (PPBP) OT1FHGQS CXCL7_HUMAN Increases Expression [29]
Serotransferrin (TF) OT41PEMS TRFE_HUMAN Decreases Expression [22]
Amyloid-beta precursor protein (APP) OTKFD7R4 A4_HUMAN Increases Expression [9]
Inhibin alpha chain (INHA) OT7HWCO3 INHA_HUMAN Decreases Expression [18]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Expression [26]
ATP synthase subunit beta, mitochondrial (ATP5F1B) OTLFZUQK ATPB_HUMAN Decreases Expression [19]
Laminin subunit beta-1 (LAMB1) OT6J9LJR LAMB1_HUMAN Increases Expression [18]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Secretion [30]
C-C motif chemokine 3 (CCL3) OTW2H3ND CCL3_HUMAN Increases Secretion [30]
60 kDa heat shock protein, mitochondrial (HSPD1) OTTO1Y11 CH60_HUMAN Affects Expression [20]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Increases Secretion [30]
Glial fibrillary acidic protein (GFAP) OTQ01ZAS GFAP_HUMAN Increases Expression [26]
D(2) dopamine receptor (DRD2) OTBLXKEG DRD2_HUMAN Decreases Expression [18]
Ezrin (EZR) OTHBPF1Z EZRI_HUMAN Decreases Expression [8]
Desmoplakin (DSP) OTB2MOP8 DESP_HUMAN Increases Expression [19]
CD44 antigen (CD44) OT9TTJ41 CD44_HUMAN Decreases Expression [18]
Transcription factor JunB (JUNB) OTG2JXV5 JUNB_HUMAN Affects Expression [26]
Transcription factor JunD (JUND) OTNKACJD JUND_HUMAN Decreases Expression [26]
Troponin I, cardiac muscle (TNNI3) OT65E12V TNNI3_HUMAN Increases Secretion [31]
Parvalbumin alpha (PVALB) OTZW1WVQ PRVA_HUMAN Decreases Expression [19]
Nucleoside diphosphate kinase B (NME2) OTCYGLHV NDKB_HUMAN Affects Expression [20]
Receptor-type tyrosine-protein phosphatase beta (PTPRB) OTCQPLGZ PTPRB_HUMAN Decreases Expression [18]
Nuclear transcription factor Y subunit beta (NFYB) OTXSE7KW NFYB_HUMAN Increases Expression [18]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [32]
ATP synthase subunit alpha, mitochondrial (ATP5F1A) OT3FZDLX ATPA_HUMAN Affects Expression [20]
Elongation factor 1-gamma (EEF1G) OTW7DH2F EF1G_HUMAN Decreases Expression [9]
CCN family member 2 (CCN2) OTC39NSU CCN2_HUMAN Decreases Expression [18]
Peroxiredoxin-5, mitochondrial (PRDX5) OTUEKZ18 PRDX5_HUMAN Affects Expression [20]
CAP-Gly domain-containing linker protein 1 (CLIP1) OTTGAEJE CLIP1_HUMAN Increases Expression [18]
Sodium-dependent serotonin transporter (SLC6A4) OT6FGDLW SC6A4_HUMAN Decreases Activity [33]
Peroxiredoxin-2 (PRDX2) OTLWCY9T PRDX2_HUMAN Decreases Expression [19]
D(3) dopamine receptor (DRD3) OT0OFFKB DRD3_HUMAN Decreases Expression [34]
Alpha-actinin-2 (ACTN2) OT9FOLD7 ACTN2_HUMAN Increases Expression [9]
Hippocalcin-like protein 1 (HPCAL1) OTOBBFRD HPCL1_HUMAN Decreases Expression [9]
Alpha-synuclein (SNCA) OTPWC1MR SYUA_HUMAN Increases Expression [35]
Beta-crystallin B2 (CRYBB2) OTL0Z8E6 CRBB2_HUMAN Decreases Expression [9]
Nuclear receptor subfamily 4 group A member 2 (NR4A2) OT3F9IR2 NR4A2_HUMAN Decreases Expression [21]
Small ribosomal subunit protein uS4 (RPS9) OTPV69Q0 RS9_HUMAN Decreases Expression [9]
Small ribosomal subunit protein eS10 (RPS10) OTE3VSAH RS10_HUMAN Decreases Expression [9]
Protein Tob1 (TOB1) OTNW949D TOB1_HUMAN Decreases Expression [9]
Protein FosB (FOSB) OTW6C05J FOSB_HUMAN Increases Expression [26]
AP-2 complex subunit sigma (AP2S1) OTEV2XGW AP2S1_HUMAN Decreases Expression [9]
GTP-binding protein GEM (GEM) OT6SK8ZV GEM_HUMAN Increases Expression [9]
Actin, gamma-enteric smooth muscle (ACTG2) OTRDWUO0 ACTH_HUMAN Decreases Expression [8]
Spectrin beta chain, non-erythrocytic 1 (SPTBN1) OTOVM4D4 SPTB2_HUMAN Decreases Expression [9]
Peptidyl-prolyl cis-trans isomerase D (PPID) OT2CDF7W PPID_HUMAN Increases Expression [18]
Semaphorin-3B (SEMA3B) OTCZCPMS SEM3B_HUMAN Increases Expression [36]
Dystrophin-related protein 2 (DRP2) OTWR7WGU DRP2_HUMAN Affects Expression [20]
Calcium/calmodulin-dependent protein kinase type II subunit beta (CAMK2B) OTS9YK3E KCC2B_HUMAN Decreases Expression [36]
Cullin-4B (CUL4B) OT2QX4DO CUL4B_HUMAN Increases Expression [9]
Endoplasmic reticulum membrane sensor NFE2L1 (NFE2L1) OT1QHOS2 NF2L1_HUMAN Increases Expression [18]
Myocyte-specific enhancer factor 2D (MEF2D) OT7CEIG0 MEF2D_HUMAN Decreases Expression [18]
Proteasome activator complex subunit 4 (PSME4) OTDGF53O PSME4_HUMAN Increases Expression [9]
Cysteine and glycine-rich protein 2 (CSRP2) OT4SW0HI CSRP2_HUMAN Decreases Expression [18]
Cocaine- and amphetamine-regulated transcript protein (CARTPT) OTTE4V9S CART_HUMAN Increases Expression [9]
Myomegalin (PDE4DIP) OTS15WNF MYOME_HUMAN Decreases Expression [32]
Adropin (ENHO) OT91QASK ENHO_HUMAN Decreases Expression [32]
Liprin-beta-1 (PPFIBP1) OTRA2S7B LIPB1_HUMAN Increases Expression [18]
Tumor protein p53-inducible nuclear protein 2 (TP53INP2) OT0GTBXO T53I2_HUMAN Decreases Expression [9]
RING1 and YY1-binding protein (RYBP) OTZZ4P2Z RYBP_HUMAN Increases Expression [18]
Programmed cell death protein 7 (PDCD7) OTK5YO7J PDCD7_HUMAN Increases Expression [18]
Neuropilin and tolloid-like protein 2 (NETO2) OT0YAMC0 NETO2_HUMAN Increases Expression [9]
Protein Churchill (CHURC1) OTCVNVQN CHUR_HUMAN Decreases Expression [9]
Connector enhancer of kinase suppressor of ras 2 (CNKSR2) OTAGERJ2 CNKR2_HUMAN Increases Expression [9]
Zinc finger protein ubi-d4 (DPF2) OTL0JH2C REQU_HUMAN Increases Expression [18]
Tumor necrosis factor receptor superfamily member 14 (TNFRSF14) OTB82PFO TNR14_HUMAN Increases Expression [8]
Protein MAL2 (MAL2) OTVPEI80 MAL2_HUMAN Increases Expression [9]
Protein TMEPAI (PMEPA1) OTY8Z9UF PMEPA_HUMAN Increases Expression [9]
Serine/threonine-protein kinase Sgk3 (SGK3) OTQ6QO99 SGK3_HUMAN Increases Expression [18]
GRIP and coiled-coil domain-containing protein 1 (GCC1) OTDOE6U8 GCC1_HUMAN Increases Expression [36]
Fumarylacetoacetate hydrolase domain-containing protein 2A (FAHD2A) OTHQP0L5 FAH2A_HUMAN Affects Expression [20]
Protein arginine N-methyltransferase 6 (PRMT6) OT5V3XIN ANM6_HUMAN Decreases Expression [37]
E3 ubiquitin-protein ligase NEDD4-like (NEDD4L) OT1B19RU NED4L_HUMAN Increases Expression [9]
Eyes absent homolog 1 (EYA1) OTHU807A EYA1_HUMAN Increases Expression [9]
Apolipoprotein L2 (APOL2) OT303Q7B APOL2_HUMAN Increases Expression [36]
Allograft inflammatory factor 1-like (AIF1L) OTDEOB80 AIF1L_HUMAN Decreases Expression [9]
Synaptotagmin-11 (SYT11) OTLRTZEI SYT11_HUMAN Increases Expression [18]
Mitochondrial adenyl nucleotide antiporter SLC25A23 (SLC25A23) OTG0B7RM SCMC3_HUMAN Decreases Expression [32]
Oxysterol-binding protein-related protein 1 (OSBPL1A) OTQ33OQV OSBL1_HUMAN Decreases Expression [9]
Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 (NUCKS1) OTL4VJC5 NUCKS_HUMAN Decreases Expression [9]
Semaphorin-6A (SEMA6A) OTDQ7QAW SEM6A_HUMAN Decreases Expression [18]
E3 ubiquitin-protein ligase MARCHF7 (MARCHF7) OTG9SF10 MARH7_HUMAN Increases Expression [18]
Serine/threonine-protein kinase PAK 6 (PAK6) OTAHPZTT PAK6_HUMAN Decreases Expression [18]
Beta-catenin-interacting protein 1 (CTNNBIP1) OTX9SBJG CNBP1_HUMAN Decreases Expression [18]
Protein lin-7 homolog C (LIN7C) OTB3015O LIN7C_HUMAN Increases Expression [18]
Mitoferrin-1 (SLC25A37) OTJ9F01S MFRN1_HUMAN Increases Expression [9]
Leucine-rich repeat transmembrane protein FLRT3 (FLRT3) OT3XMZU3 FLRT3_HUMAN Increases Expression [18]
Sodium/hydrogen exchanger 2 (SLC9A2) OTYZYSHX SL9A2_HUMAN Decreases Expression [18]
Klotho (KL) OTD4VWU6 KLOT_HUMAN Increases Expression [9]
ProSAAS (PCSK1N) OT7ZRW2F PCS1N_HUMAN Decreases Expression [9]
Protein FAM153A (FAM153A) OTNHG4S2 F153A_HUMAN Increases Expression [32]
Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 (ENPP5) OTY807N5 ENPP5_HUMAN Increases Expression [9]
Probable ATP-dependent RNA helicase DDX41 (DDX41) OT6KEIHP DDX41_HUMAN Decreases Expression [18]
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 (HCN2) OTW28QTH HCN2_HUMAN Increases Expression [18]
Protein NDRG2 (NDRG2) OT5L6KD7 NDRG2_HUMAN Decreases Expression [9]
SH3 and multiple ankyrin repeat domains protein 2 (SHANK2) OTSQTPFQ SHAN2_HUMAN Decreases Expression [18]
Paraplegin (SPG7) OT8OY9ST SPG7_HUMAN Decreases Expression [18]
Solute carrier family 22 member 14 (SLC22A14) OTHRY1XS S22AE_HUMAN Decreases Expression [18]
UDP-N-acetylglucosamine transporter (SLC35A3) OTG92DK5 S35A3_HUMAN Increases Expression [18]
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B gamma isoform (PPP2R2C) OTXK0SDM 2ABG_HUMAN Decreases Expression [9]
Protocadherin gamma-A1 (PCDHGA1) OTR1U1LI PCDG1_HUMAN Increases Expression [18]
Protocadherin alpha-2 (PCDHA2) OTAV93M9 PCDA2_HUMAN Increases Expression [18]
Mu-type opioid receptor (OPRM1) OT16AAT8 OPRM_HUMAN Increases Response To Substance [38]
Sodium-dependent dopamine transporter (SLC6A3) OT39XG28 SC6A3_HUMAN Increases Response To Substance [39]
Calcium/calmodulin-dependent protein kinase type IV (CAMK4) OT47RDGV KCC4_HUMAN Increases Response To Substance [40]
Collagen alpha-1(XXI) chain (COL21A1) OT7GS82E COLA1_HUMAN Affects Response To Substance [10]
D(4) dopamine receptor (DRD4) OTAJTO7N DRD4_HUMAN Increases Response To Substance [41]
Synaptotagmin-13 (SYT13) OTG94RJ4 SYT13_HUMAN Affects Response To Substance [10]
Dynein axonemal heavy chain 8 (DNAH8) OTGES2OU DYH8_HUMAN Affects Response To Substance [10]
Little elongation complex subunit 2 (ICE2) OTJ3BXND ICE2_HUMAN Affects Response To Substance [10]
Voltage-dependent L-type calcium channel subunit alpha-1D (CACNA1D) OTQFH2ZD CAC1D_HUMAN Affects Response To Substance [42]
CD81 antigen (CD81) OTQFXNAZ CD81_HUMAN Increases Response To Substance [43]
Kelch-like protein 5 (KLHL5) OTRDVST4 KLHL5_HUMAN Affects Response To Substance [10]
Probable phospholipid-transporting ATPase IIB (ATP9B) OTRTYQOK ATP9B_HUMAN Affects Response To Substance [10]
Glycoprotein endo-alpha-1,2-mannosidase (MANEA) OTV7L8I6 MANEA_HUMAN Affects Response To Substance [10]
Serine-rich coiled-coil domain-containing protein 1 (CCSER1) OTVLD4J3 CCSE1_HUMAN Affects Response To Substance [10]
Homer protein homolog 1 (HOMER1) OTWFD3SI HOME1_HUMAN Increases Response To Substance [44]
Teneurin-3 (TENM3) OTWY13GR TEN3_HUMAN Affects Response To Substance [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 184 DOT(s)
Indication(s) of Vigabatrin
Disease Entry ICD 11 Status REF
Alcohol dependence 6C40.2 Approved [4]
Cocaine addiction 6C45.2 Approved [4]
Complex partial seizure 8A68.0 Approved [5]
Epilepsy 8A60-8A68 Approved [5]
Infantile spasm 8A62.0 Approved [5]
West syndrome N.A. Approved [4]
Vigabatrin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
GABA transaminase (ABAT) TTT2LD9 GABT_HUMAN Inhibitor [45]
------------------------------------------------------------------------------------
Vigabatrin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Proton-coupled amino acid transporter 1 (SLC36A1) DT48WEM S36A1_HUMAN Substrate [46]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00373581) Effects of Vigabatrin on Cocaine Self-Administration
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2286).
3 Cocaine FDA Label
4 Vigabatrin FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4821).
6 Transcriptional profiling in the human prefrontal cortex: evidence for two activational states associated with cocaine abuse. Pharmacogenomics J. 2003;3(1):27-40.
7 Cocaine-induced erythrocytosis and increase in von Willebrand factor: evidence for drug-related blood doping and prothrombotic effects. Arch Intern Med. 1999 Sep 13;159(16):1925-9. doi: 10.1001/archinte.159.16.1925.
8 Gene expression profiling reveals distinct cocaine-responsive genes in human fetal CNS cell types. J Addict Med. 2009 Dec;3(4):218-26. doi: 10.1097/ADM.0b013e318199d863.
9 Gene expression profile of the nucleus accumbens of human cocaine abusers: evidence for dysregulation of myelin. J Neurochem. 2004 Mar;88(5):1211-9. doi: 10.1046/j.1471-4159.2003.02247.x.
10 Substance dependence low-density whole genome association study in two distinct American populations. Hum Genet. 2008 Jun;123(5):495-506. doi: 10.1007/s00439-008-0501-0. Epub 2008 Apr 26.
11 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
12 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
13 Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol. 1991 Jul;40(1):63-8.
14 Regenerative changes in hepatic morphology and enhanced expression of CYP2B10 and CYP3A during daily administration of cocaine. Hepatology. 1996 Mar;23(3):515-23.
15 Drug Interactions Flockhart Table
16 An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties. Chem Biol Interact. 2008 Sep 25;175(1-3):83-7.
17 Down-regulation of astroglial CYP2C, glucocorticoid receptor and constitutive androstane receptor genes in response to cocaine in human U373 MG astrocytoma cells. Toxicol Lett. 2005 Dec 15;159(3):203-11.
18 Gene expression in human hippocampus from cocaine abusers identifies genes which regulate extracellular matrix remodeling. PLoS One. 2007 Nov 14;2(11):e1187. doi: 10.1371/journal.pone.0001187.
19 Cytosolic proteomic alterations in the nucleus accumbens of cocaine overdose victims. Mol Psychiatry. 2007 Jan;12(1):55-73. doi: 10.1038/sj.mp.4001914. Epub 2006 Oct 31.
20 Proteomic analysis of the nucleus accumbens of rats with different vulnerability to cocaine addiction. Neuropharmacology. 2009 Jul;57(1):41-8. doi: 10.1016/j.neuropharm.2009.04.005. Epub 2009 Apr 22.
21 Transcription factors specifying dopamine phenotype are decreased in cocaine users. Neuroreport. 2004 Mar 1;15(3):401-4. doi: 10.1097/00001756-200403010-00003.
22 Expression of transcripts for myelin related genes in postmortem brain from cocaine abusers. Neurochem Res. 2009 Jan;34(1):46-54. doi: 10.1007/s11064-008-9655-3. Epub 2008 Mar 21.
23 Dopamine transporter-dependent induction of C-Fos in HEK cells. Synapse. 2002 Jul;45(1):52-65. doi: 10.1002/syn.10084.
24 Cocaine use and acute left ventricular dysfunction. Lancet. 2001 May 19;357(9268):1586. doi: 10.1016/S0140-6736(00)04727-9.
25 Temporal concordance of cocaine effects on mood states and neuroendocrine hormones. Psychoneuroendocrinology. 2002 Jan-Feb;27(1-2):71-82. doi: 10.1016/s0306-4530(01)00036-1.
26 Effect of acute and chronic psychostimulant drugs on redox status, AP-1 activation and pro-enkephalin mRNA in the human astrocyte-like U373 MG cells. Neuropharmacology. 2005 Apr;48(5):673-84. doi: 10.1016/j.neuropharm.2004.12.010.
27 Effects of intravenous cocaine and cigarette smoking on luteinizing hormone, testosterone, and prolactin in men. J Pharmacol Exp Ther. 2003 Oct;307(1):339-48. doi: 10.1124/jpet.103.052928. Epub 2003 Jul 31.
28 Effect of cocaine usage on C-reactive protein, von Willebrand factor, and fibrinogen. Am J Cardiol. 2002 May 1;89(9):1133-5. doi: 10.1016/s0002-9149(02)02289-0.
29 Cocaine activates platelets and increases the formation of circulating platelet containing microaggregates in humans. Heart. 2000 Jun;83(6):688-95. doi: 10.1136/heart.83.6.688.
30 Cocaine opens the blood-brain barrier to HIV-1 invasion. J Neurovirol. 1998 Dec;4(6):619-26. doi: 10.3109/13550289809114228.
31 Utility of troponin I in patients with cocaine-associated chest pain. Acad Emerg Med. 2002 Oct;9(10):1007-13. doi: 10.1111/j.1553-2712.2002.tb02134.x.
32 Distinctive profiles of gene expression in the human nucleus accumbens associated with cocaine and heroin abuse. Neuropsychopharmacology. 2006 Oct;31(10):2304-12. doi: 10.1038/sj.npp.1301089. Epub 2006 May 3.
33 Relationship of the serotonin transporter with prolactin response to meta-chlorophenylpiperazine in cocaine dependence. J Psychiatr Res. 2008 Oct;42(14):1213-9. doi: 10.1016/j.jpsychires.2008.01.008. Epub 2008 Mar 5.
34 Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. Am J Psychiatry. 2009 Oct;166(10):1170-7. doi: 10.1176/appi.ajp.2009.08121801. Epub 2009 Sep 1.
35 Cocaine abusers have an overexpression of alpha-synuclein in dopamine neurons. J Neurosci. 2003 Apr 1;23(7):2564-71. doi: 10.1523/JNEUROSCI.23-07-02564.2003.
36 Transcriptional changes common to human cocaine, cannabis and phencyclidine abuse. PLoS One. 2006 Dec 27;1(1):e114. doi: 10.1371/journal.pone.0000114.
37 Histone arginine methylation in cocaine action in the nucleus accumbens. Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):9623-8. doi: 10.1073/pnas.1605045113. Epub 2016 Aug 9.
38 Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. Am J Med Genet B Neuropsychiatr Genet. 2003 Jul 1;120B(1):97-108. doi: 10.1002/ajmg.b.20034.
39 The dopamine transporter protein gene (SLC6A3): primary linkage mapping and linkage studies in Tourette syndrome. Genomics. 1995 Dec 10;30(3):459-63. doi: 10.1006/geno.1995.1265.
40 Loss of the Ca2+/calmodulin-dependent protein kinase type IV in dopaminoceptive neurons enhances behavioral effects of cocaine. Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17549-54. doi: 10.1073/pnas.0803959105. Epub 2008 Nov 10.
41 Polymorphisms TaqI A of the DRD2, BalI of the DRD3, exon III repeat of the DRD4, and 3' UTR VNTR of the DAT: association with childhood ADHD in male African-Caribbean cocaine dependents?. Am J Med Genet B Neuropsychiatr Genet. 2007 Dec 5;144B(8):1034-41. doi: 10.1002/ajmg.b.30540.
42 Enhancing VTA Ca(v)1.3 L-type Ca(2+) channel activity promotes cocaine and mood-related behaviors via overlapping AMPA receptor mechanisms in the nucleus accumbens. Mol Psychiatry. 2017 Dec;22(12):1735-1745. doi: 10.1038/mp.2017.9. Epub 2017 Feb 14.
43 In vivo gene silencing of CD81 by lentiviral expression of small interference RNAs suppresses cocaine-induced behaviour. J Neurochem. 2005 Mar;92(5):1243-55. doi: 10.1111/j.1471-4159.2004.02961.x.
44 Association of a polymorphism in the Homer1 gene with cocaine dependence in an African American population. Psychiatr Genet. 2005 Dec;15(4):277-83. doi: 10.1097/00041444-200512000-00010.
45 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
46 Rectal absorption of vigabatrin, a substrate of the proton coupled amino acid transporter (PAT1, Slc36a1), in rats. Pharm Res. 2012 Apr;29(4):1134-42.